Notice NOT-GM-19-045 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-018 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-20-150 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications to create a Marmoset Coordination Center. The awardee will be responsible for two separate but related activities. The first activity will be to become the repository for genomic, pedigree, and event records (date of birth, medical, reproductive history) for captive marmosets. The awardee is expected to use that information to help make breeding recommendations to maximize the health and genetic diversity of the marmosets in primate colonies. Applicants are encouraged to adopt the model used by the Association of Zoos and Aquariums.

Funding Opportunity RFA-MH-20-145 from the NIH Guide for Grants and Contracts. The common marmoset has recently emerged as a promising model system to understand the primate brain. In particular, marmoset behavior is similar in many ways to human behavior and the technology for germ line transmission of exogenous genetic information is now possible. However, existing colonies and commercial sources are currently unable to provide sufficient marmosets for neuroscience research.

Funding Opportunity PAR-19-304 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasisand autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets.

Funding Opportunity PAR-19-305 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasisand autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs.

Funding Opportunity RFA-DA-20-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support the development of Clinical Outcome Assessments (COAs) for Substance Use Disorders (SUDs) aiming to be qualified by the Food and Drug Administration (FDA) as Drug Development Tools (DDTs).The FDA qualification of a COA is based on a review of the evidence to support the conclusion that the COA is a "well-defined and reliable assessment of a targeted concept(s) in a specified context of use in adequate and well-controlled investigations". Once qualified as a DDT, the COA will become a publicly available instrument and can be deployed within a specified context of use (COU) as a sensitive, reliable and validated instrument. COA can be a patient-reported outcome (PRO), a clinician-reported outcome (ClinRO), an observer-reported outcome (ObsRO) or a performance outcome (PerfO). Applications may focus on the creation and development of a new COA, or on modification/optimization of an existing COA. The final goal is to have FDA-qualified COA(s) measure(s) that would be acceptable to regulatory authorities when used in SUDs clinical trials. It is expected that such FDA-qualified COAs will have a potential to catalyze the regulatory approval path for new treatments.

Notice NOT-HL-19-710 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-703 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-302 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission.

Funding Opportunity RFA-AG-20-039 from the NIH Guide for Grants and Contracts. To date, limited evidence suggests that regulation of lipid metabolism can modulate lifespan. This funding opportunity announcement aims to encourage innovative research programs designed to improve and expand our understanding of novel regulatory mechanisms governing lipid metabolism and signaling in the context of aging and age-associated conditions.

Funding Opportunity PAR-19-301 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies, research tools, software, and/or service to a substantial user base at institutions across multiple states (regional) or the country (national). These resources should already be established, although new resources formed through consolidation of multiple local or regional facilities are also eligible. They should be poised to achieve or already have achieved significant economies of scale and should be able to significantly increase access to the supported technologies or services for researchers across one or more regions or the country. Major new research and development efforts should not be included. For this FOA, a resource is defined as an activity that provides research capabilities and expertise to a large number of investigators and is available to any qualified investigator as a service. The intent is to provide access to investigators without regard to the particular biomedical focus of their research, but not to duplicate or replace resources supported by other NIH Institutes and Centers (ICs) or host institutions. Only those resources whose technical capabilities fall within the program areas supported by NIGMS will be supported. It is expected that the resource will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support. Stand-alone data resources and databases are not eligible for funding through this FOA. This FOA is limited to applications requesting support for resources that have been developed through previous NIGMS funding.

Notice NOT-OD-19-112 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-024 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-023 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-057 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-016 from the NIH Guide for Grants and Contracts

Notice NOT-AR-19-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-19-009 from the NIH Guide for Grants and Contracts. The purpose of this Common Fund initiative is to advance the application of cryoelectron tomography (cryoET), a powerful new method for directly visualizing macromolecular associations and organization in native cells. The two FOAs for this initiative will establish a national network of service centers that will provide these services to the community: collection of high-resolution cryoET data, cryoET specimen preparation, access for users to advanced instrumentation for cryoET, and cross-training in cryoET methods. This FOA, one of two for the initiative, will establish four service centers that will specialize in cryoET specimen preparation. The other FOA, RFA-RM-19-010, will establish a network hub that will support these service centers and collect cryoET data for them.